Potential of circulating biomarkers in liquid biopsy diagnostics

Yeo, Joo Chuan; Lim, Chwee Teck

doi:10.2144/btn-2018-0093

Cited by 8 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, an objective method for quantifying MMP-13 or other molecules in SCC tissues for diagnostic purposes has not been reported. It is known that gene dysregulations caused by tumors are often reflected by the changes of final gene products in blood which can be applied for tumor diagnosis [ 40 , 41 ]. In view of this and the finding of MMP-13 up-regulation in SCC tissues, we sought to explore serum MMP-13 as a diagnostic marker for cSCC, and our results show that serum MMP-13 has high sensitivity and specificity for the differentiation of invasive cSCC and cSCC in situ (Fig.…”

Section: Discussionmentioning

confidence: 99%

Serum matrix metalloproteinase-13 as a diagnostic biomarker for cutaneous squamous cell carcinoma

Wang

Yan

et al. 2021

BMC Cancer

View full text Add to dashboard Cite

Background A significant proportion of newly diagnosed patients with cutaneous squamous cell carcinoma (cSCC) have metastasis and eventually die of the disease, necessitating the exploration of novel biomarkers for early detection of cSCC aggressiveness, risk assessment and monitoring. Matrix metalloproteinase-13 (MMP-13) has been implicated in cSCC pathogenesis. Serum MMP-13 levels have been shown to predict survival in patients with esophageal SCC, but their diagnostic value for cSCC has not been explored. Methods We conducted a case-control study to examine serum MMP-13 as a biomarker for cSCC. Patients with cSCC undergoing surgical resection and health controls undergoing plastic surgery were recruited. ELISA for measurement of serum MMP-13 and immunohistochemistry for detection of tissue MMP-13 were performed, and the results were compared between the case and the control group, and among different patient groups. ROC curve analysis was performed to determine the diagnostic value of serum MMP-13 levels. Results The ratio of male to female, and the age between the case (n = 77) and the control group (n = 50) were not significantly different. Patients had significantly higher serum MMP-13 levels than healthy controls. Subjects with stage 3 cSCC had markedly higher serum MMP-13 levels than those with stage 1 and stage 2 cSCC. Patients with invasive cSCC had remarkably higher serum MMP-13 than those with cSCC in situ. Post-surgery serum MMP-13 measurement was done in 12 patients, and a significant MMP-13 decrease was observed after removal of cSCC. Tumor tissues had a remarkably higher level of MMP-13 than control tissues. Serum MMP-13 predicted the presence of invasive cSCC with an AUC of 0.87 (95% CI [0.78 to 0.95]) for sensitivity and specificity of 81.7 and 82.4%, respectively for a cut-off value of 290 pg/mL. Serum MMP-13 predicted lymph node involvement with an AUC of 0.94 (95% CI [0.88 to 0.99]) for sensitivity and specificity of 93.8 and 88.5%, respectively for a cut-off value of 430 pg/mL. Conclusion Serum MMP-13 might serve as a valuable biomarker for early detection of cSCC invasiveness and monitoring of cSCC progression.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum matrix metalloproteinase-13 as a diagnostic biomarker for cutaneous squamous cell carcinoma

Wang

Yan

et al. 2021

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…Cell-free DNA (cfDNA) obtained from the liquid biopsy is fragmented DNA originating from deteriorating cancer cells [ 53 ]. Evaluation of alterations in DNA structure is gaining interest in the identification of cancer heterogeneity and patient prognosis.…”

Section: Cell-free Dnamentioning

confidence: 99%

Biomarkers of Bladder Cancer: Cell-Free DNA, Epigenetic Modifications and Non-Coding RNAs

Harsanyi

Nováková

Bevizova

et al. 2022

IJMS

View full text Add to dashboard Cite

Bladder cancer (BC) is the 10th most frequent cancer in the world. The initial diagnosis and surveillance of BC require a combination of invasive and non-invasive methods, which are costly and suffer from several limitations. Cystoscopy with urine cytology and histological examination presents the standard diagnostic approach. Various biomarkers (e.g., proteins, genes, and RNAs) have been extensively studied in relation to BC. However, the new trend of liquid biopsy slowly proves to be almost equally effective. Cell-free DNA, non-coding RNA, and other subcellular structures are now being tested for the best predictive and diagnostic value. In this review, we focused on published gene mutations, especially in DNA fragments, but also epigenetic modifications, and non-coding RNA (ncRNA) molecules acquired by liquid biopsy. We performed an online search in PubMed/Medline, Scopus, and Web of Science databases using the terms “bladder cancer”, in combination with “markers” or “biomarkers” published until August 2022. If applicable, we set the sensitivity and specificity threshold to 80%. In the era of precision medicine, the development of complex laboratory techniques fuels the search and development of more sensitive and specific biomarkers for diagnosis, follow-up, and screening of BC. Future efforts will be focused on the validation of their sensitivity, specificity, predictive value, and their utility in everyday clinical practice.

show abstract

“…Increasingly advanced molecular detection techniques have led to the emergence of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating tumor RNA (ctRNA), exosomes, and exosomal contents as promising tumor-related biomarkers that can be readily detected through the noninvasive sampling of biofluidsa process known as liquid biopsy. These liquid biopsy strategies have the potential to be more sensitive and specific than traditional oncogenic biomarkers, offering insight into tumor development, diagnosis, and prognostic evaluation (12)(13)(14).…”

Section: Introductionmentioning

confidence: 99%

Exosomal circRNAs as promising liquid biopsy biomarkers for glioma

Shi

Lian

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Liquid biopsy strategies enable the noninvasive detection of changes in the levels of circulating biomarkers in body fluid samples, providing an opportunity to diagnose, dynamically monitor, and treat a range of diseases, including cancers. Glioma is among the most common forms of intracranial malignancy, and affected patients exhibit poor prognostic outcomes. As such, diagnosing and treating this disease in its early stages is critical for optimal patient outcomes. Exosomal circular RNAs (circRNAs) are involved in both the onset and progression of glioma. Both the roles of exosomes and methods for their detection have received much attention in recent years and the detection of exosomal circRNAs by liquid biopsy has significant potential for monitoring dynamic changes in glioma. The present review provides an overview of the circulating liquid biopsy biomarkers associated with this cancer type and the potential application of exosomal circRNAs as tools to guide the diagnosis, treatment, and prognostic evaluation of glioma patients during disease progression.

show abstract

Potential of circulating biomarkers in liquid biopsy diagnostics

Cited by 8 publications

References 8 publications

Serum matrix metalloproteinase-13 as a diagnostic biomarker for cutaneous squamous cell carcinoma

Serum matrix metalloproteinase-13 as a diagnostic biomarker for cutaneous squamous cell carcinoma

Biomarkers of Bladder Cancer: Cell-Free DNA, Epigenetic Modifications and Non-Coding RNAs

Exosomal circRNAs as promising liquid biopsy biomarkers for glioma

Contact Info

Product

Resources

About